Table 2.
Medication and antithrombotic therapy (ATT) during the year following cohort entry
| Medication/therapy |
Total cohort (n = 3740) |
Subcohort 2010–2011 (n = 474) |
Subcohort 2012–2015 (n = 1914) |
Subcohort 2016–2017 (n = 1352) |
P∗ |
|---|---|---|---|---|---|
| ATT at 1 month following the cohort entry | (n = 3552) | (n = 451) | (n = 1812) | (n = 1289) | |
| Low-dose ASA | 3141 (88.4) | 414 (91.8) | 1613 (89.0) | 1114 (86.4) | < 0.01 |
| P2Y12 inhibitor | |||||
| Ticagrelor | 332 (9.4) | 1 (0.2) | 171 (9.4) | 160 (12.4) | < 0.01 |
| Clopidogrel | 3040 (85.6) | 426 (94.5) | 1540 (85.0) | 1074 (83.3) | < 0.01 |
| Prasugrel | 52 (1.5) | 5 (1.1) | 37 (2.0) | 10 (0.8) | 0.01 |
| Oral anticoagulant | |||||
| Warfarin | 1118 (31.5) | 223 (49.5) | 676 (37.3) | 219 (17.0) | < 0.01 |
| DOAC | 865 (24.4) | 12 (2.7) | 327 (18.1) | 526 (40.8) | < 0.01 |
| Warfarin and/or DOAC | 1945 (54.8) | 232 (51.4) | 983 (54.3) | 730 (56.6) | 0.13 |
| Combination therapy | 0.02† | ||||
| DAPT | 1407 (39.6) | 193 (42.8) | 725 (40.0) | 489 (37.9) | |
| Dual pathway‡ | 232 (6.5) | 15 (3.3) | 111 (6.1) | 106 (8.2) | |
| TATT§ | 1652 (46.5) | 209 (46.3) | 843 (46.5) | 600 (46.7) |
| ATT at 3 months following the cohort entry§ | (n = 3477) | (n = 442) | (n = 1770) | (n = 1265) | |
|---|---|---|---|---|---|
| Low-dose ASA | 2753 (792) | 394 (89.1) | 1465 (82.8) | 894 (70.7) | < 0.01 |
| P2Y12 inhibitor | |||||
| Ticagrelor | 269 (7.7) | 1 (0.2) | 143 (8.1) | 125 (9.9) | < 0.01 |
| Clopidogrel | 2478 (71.3) | 314 (71.0) | 1170 (66.1) | 994 (78.6) | < 0.01 |
| Prasugrel | 47 (1.4) | 6 (1.4) | 32 (1.8) | 9 (0.7) | 0.04 |
| Oral anticoagulant | |||||
| Warfarin | 1037 (29.8) | 206 (46.6) | 624 (35.3) | 207 (16.4) | < 0.01 |
| DOAC | 934 (26.9) | 16 (3.6) | 371 (21.0) | 547 (43.2) | < 0.01 |
| Warfarin and/or DOAC | 1935 (55.7) | 222 (50.2) | 973 (55.0) | 740 (58.5) | < 0.01 |
| Combination therapy | < 0.01† | ||||
| DAPT | 1284 (36.9) | 186 (42.1) | 657 (37.1) | 441 (34.9) | |
| Dual-pathway‡ | 478 (13.8) | 17 (3.9) | 173 (9.8) | 288 (22.8) | |
| TATT§ | 929 (26.7) | 109 (24.7) | 458 (25.9) | 362 (28.6) |
| ATT at 6 months following the cohort entry§ | (n = 3373) | (n = 431) | (n = 1710) | (n = 1232) | |
|---|---|---|---|---|---|
| Low-dose ASA | 2422 (71.8) | 375 (87.0) | 1340 (78.4) | 707 (57.4) | < 0.01 |
| P2Y12 inhibitor | |||||
| Ticagrelor | 225 (6.7) | 0 (0.0) | 116 (6.8) | 109 (8.9) | < 0.01 |
| Clopidogrel | 2119 (62.8) | 284 (65.9) | 982 (57.4) | 853 (69.2) | < 0.01 |
| Prasugrel | 42 (1.3) | 4 (0.9) | 29 (1.7) | 9 (0.7) | 0.06 |
| Oral anticoagulant | |||||
| Warfarin | 917 (27.2) | 194 (45.0) | 549 (32.1) | 174 (14.1) | < 0.01 |
| DOAC | 971 (28.8) | 20 (4.6) | 396 (23.2) | 555 (45.1) | < 0.01 |
| Warfarin and/or DOAC | 1868 (55.4) | 214 (49.7) | 931 (54.4) | 723 (58.7) | < 0.01 |
| Combination therapy | < 0.01† | ||||
| DAPT | 1178 (34.9) | 180 (41.8) | 605 (35.4) | 393 (31.9) | |
| Dual-pathway‡ | 631 (18.7) | 19 (4.4) | 198 (11.6) | 414 (33.6) | |
| TATT§ | 462 (13.7) | 79 (18.3) | 260 (15.2) | 123 (10.0) |
| ATT at 12 months following the cohort entry | (n = 3219) | (n = 411) | (n = 1639) | (n = 1169) | |
|---|---|---|---|---|---|
| Low-dose ASA | 2178 (67.7) | 340 (82.7) | 1213 (74.0) | 625 (53.5) | < 0.01 |
| P2Y12 inhibitor | |||||
| Ticagrelor | 180 (5.6) | 0 (0.0) | 87 (5.3) | 93 (8.0) | < 0.01 |
| Clopidogrel | 1668 (51.8) | 248 (60.3) | 742 (45.3) | 678 (58.0) | < 0.01 |
| Prasugrel | 35 (1.1) | 3 (0.7) | 24 (1.5) | 8 (0.7) | 0.13 |
| Oral anticoagulant | |||||
| Warfarin | 766 (23.8) | 158 (38.4) | 484 (29.5) | 124 (10.6) | < 0.01 |
| DOAC | 1036 (32.2) | 33 (8.0) | 441 (26.9) | 562 (48.1) | < 0.01 |
| Warfarin and/or DOAC | 1787 (55.5) | 188 (45.7) | 914 (55.8) | 685 (58.6) | < 0.01 |
| Combination therapy | < 0.01† | ||||
| DAPT | 982 (30.5) | 164 (39.9) | 488 (29.8) | 330 (28.2) | |
| Dual-pathway‡ | 536 (16.7) | 18 (4.4) | 173 (10.6) | 345 (29.5) | |
| TATT§ | 251 (7.8) | 53 (12.9) | 137 (8.4) | 61 (5.2) |
Values are n (%), unless otherwise indicated.
ASA, acetylsalicylic acid; ATT, antithrombotic therapy; DAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulant; TATT, triple antithrombotic therapy.
Medication at cohort entry was evaluated within the first 30 days following the discharge of the percutaneous coronary intervention (PCI) hospitalization, or within the first 30 days following the PCI diagnosis for patients not hospitalized for PCI. Medication exposure was measured within the 14 days preceding and the 14 days following the time of follow-up (1 month, 6 months, 12 months).
Significance applies to the difference among the 3 subcohorts.
P-value for the association between the 3 categories of combination therapy (mutually exclusive) and the 3 categories of subcohort.
Dual pathway: P2Y12 inhibitor + oral anticoagulant.
TATT: DAPT + oral anticoagulant.